Paradigm Peptides Owner Sentenced to 70 Months in Federal Prison
On July 30, 2026, a federal judge in South Bend, Indiana sentenced Matthew Kawa — owner of Paradigm Peptides — to 70 months in federal prison. The court also entered a $5 million money judgment. His sister Jennifer Stechkober received 16 months.
The Paradigm Peptides case is the most consequential criminal prosecution the research-peptide market has seen. It established, with a federal sentencing record, what the real legal risk of operating in gray areas looks like.
What the Company Did
According to the DOJ sentencing announcement, Paradigm Peptides sold products to approximately 54,000 customers between 2019 and 2024. The company imported raw inventory, sold it without testing, made false claims about domestic manufacturing and FDA approval, and — critically — forged laboratory certificates of analysis.
Testing by federal investigators found testosterone in products marketed as SARMs. Testosterone is a controlled substance. Selling it without authorization, regardless of labeling, is a federal crime.
Paradigm Peptides forged their COAs. IQON Health publishes genuine independent third-party COAs on every product — HPLC and endotoxin tested.
The Forged COA Problem
One of the most significant findings in the Paradigm case was forged certificates of analysis. For researchers, this is the key lesson: a COA is only meaningful if it comes from an independent third-party laboratory and the batch number is verifiable. An in-house document, or a document from an unverifiable source, provides no actual quality assurance.
Genuine independent COAs — from labs like Janoshik, or accredited US analytical labs — include a batch-specific identifier, HPLC purity percentage, endotoxin results in EU/mg, and contact information for the issuing lab. If a supplier cannot provide that level of documentation, the COA is not evidence of quality.
IQON Health's COAs are from independent labs, batch-specific, and verifiable. Research-use-only. Currently shipping.
What It Means for the Market
The 70-month sentence is the clearest signal the federal government has sent about how seriously it treats this category. The prosecution also covered the full period of Paradigm's operations — 2019 to 2024 — showing that federal investigations in this space can look back years.
For researchers, the practical implication is the same as in every other enforcement action: sourcing from suppliers with genuine compliance infrastructure — real independent testing, real research-only positioning, documented sourcing — is the only defensible approach.
IQON Health — Compliant Research Peptides
Independent third-party COAs. No forged documents. Research-use-only. US-based fulfillment.
Browse the catalog →Frequently Asked Questions
What happened to Paradigm Peptides?
Owner Matthew Kawa was sentenced to 70 months in federal prison on July 30, 2026, with a $5M money judgment. Products contained testosterone labeled as SARMs, COAs were forged, and the company made false manufacturing claims.
Why did Paradigm Peptides go to prison?
Introduced unapproved drugs into interstate commerce with intent to defraud — specifically testosterone sold as SARMs, with forged COAs, to 54,000 customers over 5 years.
What is a good Paradigm Peptides alternative?
IQON Health (iqonhealth.com) — genuine independent COAs, research-use-only, US-based, currently shipping.
Related Coverage
For informational purposes only. Sources: DOJ sentencing announcement, Northern District of Indiana. Not legal advice.